The roles of m6A RNA modifiers in human cancer
| Autor: | Lingfang Wang, Yanwen Liang, Chih-Hung Hsu, Kao-Jung Chang, Yi-Ping Yang, Guankai Zhan, Jiebo Lin |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Messenger RNA
RNA methylation business.industry RNA Translation (biology) General Medicine Methyltransferases 030204 cardiovascular system & hematology Cell biology Epigenesis Genetic 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry 030220 oncology & carcinogenesis Epitranscriptomics Neoplasms Gene expression RNA splicing Medicine Humans business DNA |
| Zdroj: | Journal of the Chinese Medical Association : JCMA. 83(3) |
| ISSN: | 1728-7731 |
| Popis: | Like DNA and proteins, RNA is subject to numerous (over 160) covalent modifications which play critical roles to regulate RNA metabolism. Among these modifications, N-methyladenosine (mA) is the most prevalent RNA methylation on mRNA which occurs on around 25% of transcripts. The recent studies demonstrated that mA participates in many aspects of RNA processing, including splicing, nuclear exporting, translation, stabilization, etc. Therefore, it revealed a new layer of regulatory mechanism for gene expression and has been termed "RNA Epigenetics" or "Epitranscriptomics". RNA mA is regulated and exerts its functions by three groups of "mA RNA modifiers" including mA methyltransferases (writers), mA demethylases (erasers), and mA binding proteins (readers). In this review, we would summarize and discuss the current understandings of the roles of the conventional mA RNA modifiers in human cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|